Last reviewed · How we verify
or Glyburide alone.
Glyburide, marketed by Bristol-Myers Squibb, is an established oral hypoglycemic agent used in the management of type 2 diabetes. The drug's key composition patent is set to expire in 2028, providing a period of market exclusivity and potential revenue stability. However, the lack of recent key trial results and the presence of generic competitors pose significant risks to its market position.
At a glance
| Generic name | or Glyburide alone. |
|---|---|
| Sponsor | Bristol-Myers Squibb |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects (PHASE1)
- Efficacy of Repaglinide in Subjects With Type 2 Diabetes (PHASE4)
- Incretin-based Drugs and Acute Pancreatitis
- Incretin-based Drugs and the Risk of Heart Failure
- Cardioprotective Effects of GLP-1 and Their Mechanisms (PHASE1)
- A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas (PHASE3)
- Sitagliptin and Endothelial Dysfunction (PHASE3)
- Interplay Between Organic Anion Transporting Polypeptide (OATP) Transporters Transporters and CYP2C9 in Glyburide Pharmacokinetics (PK) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- or Glyburide alone. CI brief — competitive landscape report
- or Glyburide alone. updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI